Therapeutic delivery · 2016
Modified biomolecule as potential vehicle for buccal delivery of doxepin.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Laffleur Flavia, Zilio Martina, Shuwisitkul Duangratana
Аннотация
AIM: Doxepin is a traditional tricyclic antidepressant with analgesic and anesthetic properties when applied topically to the mucosa. Doxepin is one approach in treating insomnia and depression in Parkinson's disease. Patients with Parkinson's disease suffer difficulties in swallowing. Therefore, it was the aim of this study to develop a buccal-adhesive delivery system.
METHODS: Pectin was modified with cysteine. Stability assays in form of disintegration assay according to the Ph.Eur were performed. Furthermore, bioadhesiveness on buccal mucosa was investigated incorporating the drug doxepin.
RESULTS: The adhesiveness was improved 1.4-fold and revealed a sustained release over 3 h.
CONCLUSION: Taking these findings into account, the modifications render this designed excipient fruitful for buccal delivery.
METHODS: Pectin was modified with cysteine. Stability assays in form of disintegration assay according to the Ph.Eur were performed. Furthermore, bioadhesiveness on buccal mucosa was investigated incorporating the drug doxepin.
RESULTS: The adhesiveness was improved 1.4-fold and revealed a sustained release over 3 h.
CONCLUSION: Taking these findings into account, the modifications render this designed excipient fruitful for buccal delivery.